Vientiane, Laos - September 20, 2024 - BigBear Pharma, a leading biopharmaceutical company focused on developing and commercializing innovative cancer treatments, today announced that 2 products have been approved by the Ministry of Health of Laos.
Approved drugs are:
Letermovir: sold under the brand name LETEDX.Letermovir is an antiviral drug for the treatment of cytomegalovirus infections. It has been tested in CMV infected patients with allogeneic stem cell transplants and may also be useful for other patients with a compromised immune system such as those with organ transplants or HIV infections.
Cytomegalovirus (CMV) is an illness you get from a herpes virus (an organism that uses your cells to make more copies of itself). Many people will get infected in their lifetime, but most will have mild or no symptoms. CMV can cause serious complications in people living with a compromised immune system.
People who are pregnant can pass CMV to the fetus, which can cause congenital CMV. Congenital CMV is a condition that’s present at birth and can lead to hearing loss or developmental issues.
Retrieved September 20，2024, From https://www.bigbearpharma.com/en/newsroom/336.html
Prev：This is the latest article
Next：BIGBEAR Pharmaceutical announces the approval of Adagrasib in Laos
BIGBEAR Pharmaceutical announces the approval of Selumetinib…
Unlocking Global Health Opportunities: Mitotane (MITODX)
13 targeted therapies for Ｍultiple Myeloma(MM)
13 terapias dirigidas para el Mieloma Múltiple(MM)
2 targeted drugs for treatment of the KRAS mutations cancer
Copyright © 2021-2022 LienTeh.net All rights reserved.
